ClinicalTrials.gov lists 2 registered trials of BPC-157: 2 recruiting or about to, 0 running, 0 completed. Recruiting sites are in United States, China. The largest is BPC 157 for Acute Hamstring Muscle Strain Repair (120 people).
Not yet recruitingPhase 130 peopleRandomizedUniversity of Arkansas2027-01-01 → 2027-08-01🇺🇸 United States
Studying: Rotator Cuff Tear · NCT07803250
About this trial
This study is a randomized, double-blind, placebo-controlled pilot trial investigating the effects of BPC-157 on tendon healing and functional recovery following arthroscopic rotator cuff repair (aRCR). BPC-157 is a synthetic peptide that has demonstrated promising regenerative and anti-inflammatory effects in preclinical animal models of musculoskeletal injury, but it has not yet been studied in formal human clinical trials.
Twenty patients undergoing aRCR will be enrolled and randomly assigned to receive either BPC-157 or a saline placebo. Participants will self-administer subcutaneous inje…
This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.
Registered trials include ones that haven't published results yet. Trials are matched on the compound's name and code names (BPC-157, BPC 157, PL 14736, PL-14736, pentadecapeptide BPC) in the listed interventions.